All In Biotech

Drug Trial Radar · NCT07264673

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 17, 2025

Primary completion

Oct 2027

Study completion Oct 2029

Sponsor

Lead sponsor
Fondazione Ricerca TraslazionaleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients not progressing after 4 cycles of chemo-immunotherapy.

Conditions

  • NSCLC

Interventions

  • TedopiDrug

    Cemiplimab + OSE2101 (TEDOPI®) (ARM B: experimental arm)

  • CemiplimabDrug

    Cemiplimab +/-Pemetrexed (ARM A: standard arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ctDNA clearance rateTime frame: 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena

    Roma, RM, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.